Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Januar 2015 08:00 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy

SANTA MONICA, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
19. Januar 2015 15:00 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process

SANTA MONICA, Calif., Jan. 19, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
09. Januar 2015 08:00 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations

SANTA MONICA, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
08. Januar 2015 17:14 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law

SANTA MONICA, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
07. Januar 2015 13:00 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers

SANTA MONICA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
07. Januar 2015 08:00 ET | Quelle: Kite Pharma, Inc.

Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference

SANTA MONICA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
06. Januar 2015 08:00 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy

SANTA MONICA, Calif., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
30. Dezember 2014 08:30 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

SANTA MONICA, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
22. Dezember 2014 12:40 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma

SANTA MONICA, Calif., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
16. Dezember 2014 08:00 ET | Quelle: Kite Pharma, Inc.

Kite Pharma Added to the NASDAQ Biotechnology Index

SANTA MONICA, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE),a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...

Vorherige Seite

Nächste Seite